Why the Neuren (ASX:NEU) share price is moving higher today

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is treading higher today after announcing strong progress on its milestone targets.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are trending higher in early afternoon trade. This comes after the biotech company announced it has successfully completed manufacturing a drug substance for its Phase 2 trials.

At the time of writing, the Neuren share price has jumped to an intraday high of $1.28, up 1.99% for the day so far.

What did Neuren announce?

The Neuren share price is edging higher as investors appear pleased with the company's progress.

According to its release, Neuren's second drug candidate, NNZ-2591, has been manufactured ahead of Phase 2 trials. The company is currently preparing to submit Investigational New Drug (IND) applications to the United States Food and Drug Administration (FDA). If approved, this will enable Neuren to run clinical trials in children who suffer from Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome.

Neuren's latest announcement ticks off four of the milestones the company set out for 2021 in a recent corporate presentation. At current, five remaining checkpoints are still to be completed. These include:

  • Submission of the NNZ-2591 IND to the FDA.
  • Completing patient enrolment in the trofinetide Rett syndrome Phase 3 study.
  • Commencing NNZ-2591 Phase 2 trials.
  • Achieving orphan designation status in the United States and Europe for Prader-Willi syndrome.
  • Compiling results from the Trofinetide Rett syndrome Phase 3 trial (result highlights to be released in Q4 2021).

Commentary from the CEO

Neuren CEO Jon Pilcher hailed the company's developments, saying:

We have successfully developed a proprietary process for large scale manufacturing with exceptional purity and high yield. This is a key part of the strong foundations we have built for NNZ-2591, which can now be leveraged across multiple valuable indications.

As well as supplying the upcoming trials in Phelan-McDermid, Angelman and Pitt Hopkins, the campaign has produced enough drug substance at no extra cost to supply a Phase 2 trial in Prader-Willi syndrome.

Neuren share price performance overview

The Neuren share price has been a weak performer over the past 12 months, falling by nearly 28%. Neuren shares took a wild ride last year, hitting a low of 96.5 cents in March before accelerating to $1.845 in June.

Based on the current share price, Neuren has a market capitalisation of around $144 million.

Should you invest $1,000 in Bhp Group right now?

Before you buy Bhp Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bhp Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Happy woman working on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant end to the trading week for investors this Friday.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Opinions

If I had a big cash pile like Warren Buffett, here's how I'd spend it in 2025

I'd put Buffett's billions to work straight away.

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Up 30% in a month, this ASX 200 tech share is 'a compelling opportunity': expert

Analysts from listed investment company WAM Capital say this ASX 200 tech stock is worth watching.

Read more »

Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
52-Week Highs

5 ASX 200 shares hitting multi-year highs after strongly rebounding from tariff turmoil

These stocks have hit new price milestones amid a day in the green for the ASX 200.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Share Market News

3 key takeaways from the 2025 Macquarie Conference

More than one hundred companies presented at the Macquarie Conference this year. Here’s what we learned.

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why Chrysos, GQG Partners, Macquarie, and Webjet shares are storming higher today

These shares are ending the week on a positive note. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Share Gainers

The top 3 ASX 200 trades since the Liberation Day dip

These companies are up at least 35% in just over a month.

Read more »